An observational study in Type 1 Diabetes, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 2 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver — 10 open to participants now, 13 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Colorado, Denver.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 53rd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →10 of the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 10–20
University of Colorado, Denver · Sites in United States
Ages 18–89
University of Colorado, Denver · Sites in United States
Ages 14–19
University of Colorado, Denver · Sites in United States
Ages 14–26
University of Colorado, Denver · Sites in United States
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 2 Years to 26 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 8
First in 1993; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 44 across the 44 interventional studies, 85 across the 14 observational. Of the 43 that completed or were terminated, 19 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
6 of the studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05819138Phase 3University of Colorado, DenverType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | 2027-10-01 |
| NCT07494188University of Colorado, DenverSleep Screening and Intervention for Adolescents With Type 1 Diabetes in a Clinical Diabetes Center | 2026-12-01 |
| NCT07011147University of Colorado, DenverPrimary Care Pragmatic, Real World Experience for Automated Insulin Delivery | 2027-06-30 |
| NCT05319990University of Colorado, DenverPathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study) | 2027-06-30 |
| NCT07720388University of Colorado, DenverSupporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is assessing the accuracy of continuous glucose monitors during surgical procedures requiring anesthesia.
This study is an observational study design that includes collection of continuous glucose data and venous blood glucose data (from either an IV or fingerstick) from a blood glucose meter. All subjects will be undergoing a surgical procedure that requires anesthesia. The primary outcome of this study is to evaluate the accuracy of the CGM glucose values in comparison to the reference glucometer glucose value during anesthesia. There is currently limited data on accuracy of CGMs during these events and therefore it is not know whether CGM glucose data is reliable to be used as the sole source of glucose monitoring during surgery.
All participants will have a clinical diagnosis of type 1 diabetes and be wearing a continuous glucose monitor as part of routine care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric patients who are undergoing a surgical procedure with anesthesia. Patients will have type 1 diabetes and be wearing a continuous glucose monitor as part of routine care.
Accuracy of CGM compared to blood glucose using standard statistical methods including mean absolute relative difference (MARD).
Accuracy assessment will be completed comparing CGM glucose values to blood glucose values using standard statistical assessments.
Time frame: Perioperatively (length of time will vary based on the operative procedure)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 39 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →